Global initiative for chronic obstructive lung disease 2022

Global initiative for chronic obstructive lung disease 2022

European Respiratory Journal 2001 18: 901-902; DOI: 10.1183/09031936.01.0027401

What is global initiative for chronic obstructive lung diseases?

In January 1997, chronic obstructive pulmonary disease (COPD) experts from several countries met in Brussels, Belgium to explore the development of a Global Initiative for Chronic Obstructive Lung Disease (GOLD). Representatives of the National Heart, Lung and Blood Institute, USA (NHLBI) and of the World Health Organization (WHO) attended. Participants agreed that the project was timely and important, and recommended the establishment of a panel with expertize on a wide variety of COPD-related topics to prepare an evidence-based document on diagnosis, management, and prevention of COPD as a tool for GOLD. From 1998–2000, the panel members met several times to prepare the document (see further). In 2001, the GOLD initiative was firmly launched in collaboration with NHLBI and WHO. The project was, and continues to be, supported by unrestricted educational grants from a multitude of pharmaceutical companies.

The goals of GOLD are to increase awareness of COPD and decrease morbidity and mortality from this disease. GOLD aims to improve prevention and management of COPD through a concerted worldwide effort of people involved in all facets of healthcare and healthcare policy, and to encourage a renewed research interest in this extremely prevalent disease.

Why global initiative for chronic obstructive lung diseases?

COPD is a major cause of chronic morbidity and mortality throughout the world 1. COPD is currently the fourth leading cause of death in the world 2, and further increases in the prevalence and mortality of the disease can be predicted in the coming decades. In 1990, COPD ranked twelfth as cause of disability-adjusted life years (DALYs) lost worldwide 3–6. DALY is the sum of the life years lost to premature death and to disability. This measure reflects the burden of a disease on the society. It is predicted that by 2020 COPD will be the third leading cause of death and the fifth leading cause of lost DALYs worldwide. As a community of people who care for and are interested in respiratory diseases, it is time that a major effort is focused on this disease. A nihilistic attitude toward COPD has arisen among some healthcare providers, due to the relatively limited success of primary and secondary prevention (i.e. avoidance of factors that cause COPD or its progression), the prevailing notion that COPD is largely a self-inflicted disease, and disappointment with available treatment options. The same arguments could be used for many other highly prevalent diseases, including the major cardiovascular diseases. This has, however, not precluded great basic and clinical research efforts and successful prevention campaigns for these diseases.

Global initiative for chronic obstructive lung disease documents

One strategy to help achieve GOLD's objectives is to provide healthcare workers, healthcare authorities, and the general public with state-of-the-art information about COPD and specific recommendations on the most appropriate management and prevention strategies. The GOLD workshop report, Global Strategy for the Diagnosis, Management, and Prevention of COPD, is based on the best-validated current concepts of COPD pathogenesis and the available evidence on the most appropriate management and prevention strategies 1. An expert panel has developed the GOLD workshop report. NHLBI and WHO staff, in concert with the original group, identified individuals from many regions of the world to serve on the expert panel, which included health professionals in the areas of respiratory medicine, epidemiology, pathology, socioeconomics, public health, and health education.

The process was initiated by a review of all existing COPD guidelines and an extensive review of the literature on the issues that showed disagreement between these guidelines. During the writing of the draft form of the document, further literature searches were performed. The draft conclusions were presented at a European Respiratory Society (ERS) and an American Thoracic Society (ATS) symposium for an open peer discussion. The final draft was then sent around for comments to individual COPD experts and to the major respiratory societies. The final GOLD workshop report incorporates many of their comments, and thus, provides state-of-the-art information about COPD for pulmonary specialists and other interested physicians. The document includes levels of evidence for the various management recommendations.

The workshop report has also been used as the basis for the development of more concise and practical documents. An executive summary has been published in the American Journal of Respiratory and Critical Care Medicine and as a National Institute of Health (NIH) publication 7, 8. A “Pocket Guide to COPD Diagnosis, Management and Prevention, a guide for physicians and nurses” is available as a NIH publication 9. A small guide for patients and their families is currently in development. All documents can be obtained from the GOLD Secretariat located at the Dept of Respiratory Diseases, University Hospital, De Pintelaan 185, B9000 Ghent, Belgium.

All documents as well as a slide kit are available and can be downloaded from the GOLD website 10.

Where do we go from here and what can you do about it?

Writing and publishing guidelines is a futile effort if not implemented. A major task is improving the early diagnosis, management and prevention of COPD. It is encouraging to note that many international and national respiratory societies (ATS, American College of Chest Physicians, Asian Pacific Society of Respirology, Latin American Thoracic Society, ERS) have decided to endorse the GOLD project. Many societies and individuals (GOLD launch leaders) have committed themselves to the implementation of GOLD. Their names can be found on the GOLD website.

Everyone is invited to actively participate in their national programmes or even to start one, if there is not yet one up and running. As a society and community of respiratory physicians, chronic obstructive pulmonary disease must be taken on as a major health problem.

    • © ERS Journals Ltd

    References

    1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report. Bethesda, National Heart, Lung and Blood Institute, 2001; NIH Publication No 2701: 1–100.

    2. World Health Organization. World Health Report 2000. Geneva, World Health Organization, 2000.

    3. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269–1276.

    4. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997;349:1498–1504.

    5. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436–1442.

    6. Murray CJ, Lopez AD. Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: global Burden of Disease Study. Lancet 1997;349:1347–1352.

    7. Global Initiative for Chronic Obstructive Lung Disease. Executive Summary: Global Strategy for the diagnosis, management and prevention of Chronic Obstructive Pulmonary Disease. Bethesda, National Heart, Lung and Blood Institute, National Institutes of Health, 2001; NIH Publication No 2701A: 1–30.

    8. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256–1276.

    9. Global Initiative for Chronic Obstructive Lung Disease. Pocket Guide to COPD diagnosis, management and prevention. A guide for physicians and nurses. Bethesda: National Heart, Lung and Blood Institute, National Institutes of Health, 2001; NIH Publication No 2701B: 1–23.

    View Abstract

    How do you cite the GOLD Report 2022?

    Lancet Respir Med. 2022 Feb;10(2):e20. doi: 10.1016/S2213-2600(21)00561-0.

    What is new in COPD treatment?

    This new procedure, known as targeted lung denervation, brings hope of an additional treatment possibility for patients suffering from frequent COPD flare-ups, or exacerbations. It uses radio wave energy to disrupt nerve cell transmission, relaxing the airways and diminishing mucus production.

    Is there a new procedure for COPD?

    One of the newest treatment options for severe emphysema is a minimally invasive procedure called bronchoscopic lung volume reduction (BLVR) using endobronchial valves. These tiny devices are implanted in the airways of the lungs and act as one-way valves.

    What is the international guideline of COPD called?

    COPD is included in the WHO Global Action Plan for the Prevention and Control of Noncommunicable Diseases (NCDs) and the United Nations 2030 Agenda for Sustainable Development.